TG Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.
CEOMichael Sean Weiss
CEOMichael Sean Weiss
Employees264
Employees264
HeadquartersMorrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded1993
Founded1993
Employees264
Employees264
TGTX Key Statistics
Market cap2.54B
Market cap2.54B
Price-Earnings ratio72.02
Price-Earnings ratio72.02
Dividend yield—
Dividend yield—
Average volume5.38M
Average volume5.38M
High today$16.76
High today$16.76
Low today$15.56
Low today$15.56
Open price$16.20
Open price$16.20
Volume8.55M
Volume8.55M
52 Week high$35.67
52 Week high$35.67
52 Week low$6.46
52 Week low$6.46
TGTX News
Seeking Alpha 2d
TG Therapeutics jumps as Q1 Briumvi sales top guidanceTG Therapeutics (NASDAQ:TGTX) shares rose ~26% in the premarket on Wednesday after the biotech exceeded expectations with its Q1 2024 revenue, as U.S. sales fro...
Yahoo Finance 2d
TG Therapeutics Reports Q1 Loss, Tops Revenue Estimates - Yahoo FinanceTG Therapeutics (TGTX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.28...
Yahoo Finance 2d
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update - Yahoo FinanceTG Therapeutics, Inc. Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics,...
Analyst ratings
75%
of 8 ratingsBuy
75%
Hold
12.5%
Sell
12.5%
More TGTX News
Yahoo Finance 3d
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics - Yahoo FinanceTG Therapeutics (TGTX) has been on a downward spiral lately with significant selling pressure. After declining 9.8% over the past four weeks, the stock looks we...
